Survodutide
Also known as: GLP-1/glucagon dual agonist, BI 456906
Summary
An investigational GLP-1/glucagon dual agonist studied for weight loss and metabolic liver disease.
How it works
Combines GLP-1 appetite suppression with glucagon-driven energy expenditure; studied for MASH/NASH liver outcomes.
What it’s studied for
- Weight reduction in trials
- Studied for metabolic liver disease
- Dual-receptor mechanism
Research-reported protocol
Clinical trials titrate weekly subcutaneous dosing; investigational and not approved.
Route: Subcutaneous (weekly). These are amounts described in the research literature — not an instruction to administer anything.
Reconstitution — run the numbers
The same calculator the coach uses. Enter a vial size, water, and a dose to see the exact draw on a U-100 syringe.
Reconstitution
live · real mathDraw to
on a U-100 syringe
10units
2,500
mcg/mL
0.1
mL/dose
20
doses/vial
Show the math
- Concentration2,500 mcg/mL
vial mg ÷ water mL × 1,000
5 mg ÷ 2 mL × 1,000
- Volume per dose0.1 mL
dose mcg ÷ concentration
250 mcg ÷ 2,500 mcg/mL
- Units to draw10 units
mL per dose × 100
0.1 mL × 100
- Doses per vial20 doses
vial mcg ÷ dose mcg (rounded down)
5,000 mcg ÷ 250 mcg
Calculated, not guessed — the same math the app and coach use. Double-check it yourself.
The exact math, shown in the open. Full tool at the calculator.
Cautions
- Investigational; not approved
- GI side effects reported
Evidence & sources
Written by Titria Research Team.
A credentialed reviewer (PhD/PharmD) and a primary-literature citation list are still being added — we show this state honestly rather than implying a review that hasn’t happened. It means the sign-off is pending, not that the entry is unsupported. See how we rate evidence.
Check the primary literature yourself — testing our labels is encouraged.
Often studied alongside
Model a Survodutide protocol for your goals.
The coach interviews you, grounds every dose in this database and the calculator above, and saves a research protocol — never a hallucinated number.